The verified directory of US psychedelic therapy providers.

First state with a regulated adult-use psilocybin services program (Measure 109, operational since January 2023). Any adult 21+ can book a licensed session; no medical diagnosis or referral required. Over 30 licensed service centers operate under the Oregon Psilocybin Services (OPS) division of OHA.

Voters passed Proposition 122 in 2022 creating the Natural Medicine Health Act. Regulated healing centers began operating in 2025 under the Colorado Department of Regulatory Agencies (DORA). Program covers psilocybin initially; DMT, ibogaine and mescaline are scheduled to be added in later phases.

Oakland, Santa Cruz, Berkeley, San Francisco and Arcata have decriminalized possession of plant-based psychedelics. Statewide SB 1012 (Therapeutic Psilocybin Act) is in legislative review. No licensed psilocybin program yet; ketamine and Spravato are widely available in all major metros.

Assembly Bill A114 would authorize a regulated psilocybin program modelled on Oregon. Senate companion in committee. In the meantime, NYC is the densest US market for IV ketamine and Spravato, with multiple concierge and insurance-accepting practices.

HB 1802 (2021) funded a psilocybin research study at Baylor College of Medicine; no treatment program yet. Ketamine and Spravato are widely available. Texas has the second-largest number of ketamine clinics after California.

No state psychedelic legislation. Large snowbird ketamine market around Bonita Springs, Naples and Palm Beach. Spravato coverage via Florida BCBS, Aetna and several Medicare Advantage plans.

Somerville, Cambridge, Northampton and Salem have decriminalized plant-based psychedelics. Question 4 (statewide psilocybin) failed in 2024 but is expected to return on a future ballot. Strong Spravato coverage via Mass General Brigham network and Tufts Health Plan.

Seattle and Port Townsend decriminalized in 2021. SB 5263 (2024) established a state psilocybin task force that reported recommendations in early 2026. Ketamine is widely available; Spravato coverage via Regence BCBS and Premera.

CURE Act (SB 2308) would create a regulated psilocybin services program. Still in committee. Chicago is a solid ketamine/Spravato market with BCBS IL covering Spravato for MDD and MDSI.

SB 1570 (2023) funded $5M in psilocybin research grants. Policy momentum building. Ketamine scene centered on Scottsdale and Phoenix, catering to wellness and recovery markets.

No psilocybin legislation on the horizon. Ketamine and Spravato widely available in Atlanta metro. Emory Healthcare runs the largest academic psychedelic treatment program in the Southeast.

HF 1884 created a Psychedelic Medicine Task Force that reported to the legislature in 2024. Bill to establish a regulated program expected to be reintroduced in 2026 session. Mayo Clinic and University of Minnesota are active research sites.

HB 5396 (2023) established a working group on psychedelic-assisted therapy. Follow-on legislation HB 5143 passed the House in 2024. Hartford and New Haven have established Spravato and ketamine practices, with Yale Psychiatry running research trials.

S2283 Psychedelic Research Council Act passed the Senate in 2024. A broader Psilocybin Behavioral Health Access Act (S2934) is in committee. Strong Spravato coverage via Horizon BCBS and AmeriHealth. Large ketamine market in Northern NJ serving the NYC metro.

Medical Psilocybin Act (SB 219) was signed into law in April 2025, creating a medical psilocybin program for PTSD, treatment-resistant depression, substance use disorder and end-of-life care. Rule-making is in progress; first licensed practitioners expected in 2026. Ketamine and Spravato widely available.

AB 245 (2023) created a Regulated Psychedelic-Assisted Therapy Working Group that reported in 2024. Las Vegas has a concentrated ketamine clinic market serving the resort and convention travel economy, plus strong veteran-focused practices near Nellis AFB.

SB 266 (2024) authorized a psilocybin and MDMA pilot at University of Utah Health and Intermountain Health for treatment-resistant conditions. Pilot participants only; not a public program. Ketamine and Spravato widely available in the Wasatch Front.

H.439 (2023) established a Psychedelic Therapy Advisory Working Group. Burlington decriminalized plant-based psychedelics in 2024 (lowest enforcement priority). Small but growing ketamine clinic presence in Chittenden County.

Ann Arbor, Detroit, Hazel Park, Ferndale and Ypsilanti have decriminalized plant-based psychedelics. Statewide Michigan Psilocybin Services Act (SB 631) is in committee. Strong Spravato presence via Henry Ford Health and University of Michigan.

HB 175 (2024) would establish a regulated psilocybin services program; still in committee. The Ohio State University and Cleveland Clinic both operate psychedelic research trials. Ketamine availability is strong across all three major metros.

HB 1280 (2023) directed the Department of Drug and Alcohol Programs to study psilocybin for treatment-resistant conditions. Philadelphia and Pittsburgh have established ketamine and Spravato markets. Penn Medicine runs multiple psychedelic research trials.

SB 139 (2024) authorized a psilocybin research fund administered through IU School of Medicine. No public access program. Ketamine and Spravato are available in Indianapolis and other metros; Eskenazi Health runs a ketamine clinic for underinsured patients.

HB 1015 (2024) would create a Psychedelic Treatment Fund for veterans and first responders. Still in committee. Johns Hopkins runs the most influential academic psychedelic research program in the US; clinical access is via trial enrollment.

LD 1582 Psilocybin Services Act was reintroduced in 2025 and has bipartisan support. Would model after Oregon. Portland has a small but reputable ketamine clinic scene; MaineHealth operates the main Spravato site.

Multiple psilocybin bills have been introduced (SB 415, HB 2630) proposing a Hawaii Breakthrough Therapy Task Force. Ketamine and Spravato are available on Oahu and Maui; small market due to population size.

HB 753 (2024) would establish a Psychedelic Advisory Council. A Right to Try bill (HB 458) passed in 2022 allowing terminal patients to access investigational psychedelics - one of the first state-level pathways. Strong military/veteran market due to Hampton Roads and DC metro.

HB 1154 (2024) would create a psilocybin access pilot for veterans, first responders and end-of-life care patients. Saint Louis has an established ketamine and Spravato market; Washington University runs active psychedelic research.

No state psychedelic legislation. Research activity through Duke and UNC. Ketamine and Spravato widely available in the Research Triangle and Charlotte; large veteran population around Camp Lejeune.

No state psychedelic legislation pending. Vanderbilt University is active in ketamine research. Nashville has a fast-growing ketamine clinic market driven by the city's medical and entertainment economies.

No state psychedelic legislation moving. Madison and Milwaukee have established clinic markets. University of Wisconsin is active in MDMA-assisted therapy research.

No state psychedelic legislation. Ketamine and Spravato available in Birmingham, Huntsville and Mobile. UAB runs limited ketamine research.

No state psychedelic legislation. Small market limited to Anchorage and Fairbanks. Alaska Native Medical Center serves a large indigenous patient population.

No state psychedelic legislation pending. Little Rock is the market hub. UAMS operates the state's primary academic psychiatric program.

No state legislation moving. Wilmington has a small ketamine and Spravato market, often serving patients from the Philadelphia metro.

No state psychedelic legislation. Boise is the market hub. Idaho is a physician-shortage state for psychiatric care, so clinic availability is concentrated.

No state psychedelic legislation pending. Des Moines and Iowa City are the market hubs. University of Iowa runs ketamine research and a Spravato clinic.

No state psychedelic legislation. Kansas City metro (split with Missouri) is the primary market. University of Kansas Medical Center operates the main academic site.

No active psychedelic legislation. Kentucky did explore ibogaine for opioid use disorder via a 2023 state opioid fund vote, though allocations were later redirected. Louisville and Lexington are the primary markets.

No state psychedelic legislation. New Orleans and Baton Rouge are the primary markets. LSU Health and Ochsner operate the main academic Spravato programs.

No state psychedelic legislation. Small market concentrated in Jackson and the Gulf Coast. University of Mississippi Medical Center is the main academic site.

No state psychedelic legislation moving. Billings, Missoula and Bozeman are the market hubs. Long driving distances can make follow-up ketamine sessions logistically challenging.

No state psychedelic legislation. Omaha and Lincoln are the market hubs. University of Nebraska Medical Center operates the primary academic Spravato clinic.

No state psychedelic legislation moving. Manchester and the Seacoast region (Portsmouth) are the primary markets. Many patients cross into Massachusetts for Boston-area Spravato clinics.

No state psychedelic legislation. Very small market limited to Fargo and Bismarck. Sanford Health runs the primary regional Spravato program.

No state psychedelic legislation pending. OKC and Tulsa are the market hubs. Oklahoma did consider psilocybin research legislation in 2023 but it did not advance.

No state legislation moving. Small market concentrated in Providence. Butler Hospital and Brown University Health run the main academic Spravato programs.

No state psychedelic legislation. MUSC runs psychedelic research. Charleston and Columbia are the market hubs; Greenville has a growing clinic footprint.

No state psychedelic legislation. Very small market; Sioux Falls is the primary hub. Many patients travel to Minnesota or Iowa for specialty psychiatric care.

No state psychedelic legislation. WVU Medicine operates the main academic program. High unmet mental-health need driven by the regional opioid crisis, though clinic supply is limited.

No state psychedelic legislation. Smallest market by population. Cheyenne and Casper are the main hubs. Many patients travel to Denver for specialty care.

Initiative 81 (2020) made enforcement of plant-based psychedelic possession the lowest priority for MPD. Concentrated ketamine and Spravato market serving federal workforce, with strong veteran presence via VA Medical Center.